Neovia Oncology Inc.
Show jobs for this employer
About Neovia Oncology Inc.
Neovia develops oncology drugs that enhance immunotherapy response to overcome drug resistance and has begun a Phase 1 clinical trial designed to evaluate our lead multi-inhibitor, (NEV-801), that has the potential to treat patients with advanced drug-resistant cancers.Normally, immunotherapy rarely controls clinically significant tumors that fail to express target antigens, and thereby fail to elicit an effective immune response. However, there is mounting evidence that tumor antigen production can be deliberately stimulated to promote immune recognition and response.
LEADERSHIP:
Founder and CEO: Trevor Blake
Co-Founder: Raymond Su
COO: Gerald Su
CLINICAL TRIAL:
Please click here for clinical trial information.
2 articles about Neovia Oncology Inc.
-
With Completion of Neovia Acquisition, ADM Creates Premier Global Leader in Animal Nutrition
2/1/2019
Combined animal nutrition business one of the largest in the world, with estimated sales of $3.5 billion, and full range of animal nutrition products and solutions for customers globally.
-
Neovia Oncology Release: Seattle Biotech Company Begins Clinical Trial For Immunotherapy Enhancing Cancer Drug
1/25/2017